JUVEDERM VOLUMA XC PP
Generic Name and Formulations:
Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant.
Indications for JUVEDERM VOLUMA XC:
Cheek augmentation to correct age-related mid-face volume deficit.
See full labeling. Inject slowly with least amount of pressure necessary. Wait 3 secs after injecting first small amount before proceeding with rest of the inj. May use supplementary anesthesia during and post-inj. >21yrs: Individualize. Give as small boluses (0.1–0.2mL) by deep inj (subcutaneous and/or supraperiosteal). Max limit: 20mL/60kg per year. May require touch-up treatments to achieve desired effect.
History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins, lidocaine.
Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occur. Risk of infection. Defer if active inflammatory process or infection is present at specific sites. Use in non-mid-face areas: not established. Skin injury near treatment site. Known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders: not studied. Advise patients to avoid strenuous exercise, extensive sun or heat exposure within first 24hrs. Patients (<35yrs or >65yrs), pregnancy, nursing mothers: not established.
Caution with concomitant immunosuppressants. Increased bruising or bleeding risk at inj sites with concomitant aspirin, NSAIDs, warfarin.
Inj site reactions (eg, tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration, itching); rare: vision impairment, blindness, cerebral ischemia/hemorrhage, stroke, skin necrosis, facial structure damage, late-onset nodules.
Single-use syringe—1 (w. needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed